Similar results of increased tumor reduction and reduced numbers of Tregs, M2-TAMs, and MDSCs were seen in A20 lymphoma and CT26 colorectal mouse models with combination duvelisib and anti-PD-1 antibody therapy versus anti-PD-1 therapy alone (120). Here, PDCD1 is linked to lymphoma.